Cost-effectiveness of prescreening versus empirical vaccination for hepatitis A in Egyptian children with chronic liver disease
AbstractThe aim of the study was to determine the prevalence of anti-hepatitis A virus [anti-HAV] antibodies among 172 children with chronic liver disease, and to calculate the cost- effectiveness of prescreening prior to hepatitis A vaccination. Anti-HAV antibodies were positive in 85.1%. However, seroprevalence of anti-HAV antibodies was 62.1% in children < 5 years and 94.4% in children 5+ years. We conclude that while it is cost-effective to do prescreening before hepatitis A vaccination for children with chronic liver disease aged 5+ years, prescreening might not be cost-effective in those aged < 5 years
El Karaksy, H., El Sayed, R., El Raziky, M., El Koofy,N. & Mansour, S. (2008). Cost-effectiveness of prescreening versus empirical vaccination for hepatitis A in Egyptian children with chronic liver disease. EMHJ - Eastern Mediterranean Health Journal, 14 (4), 804-809, 2008 http://www.who.int/iris/handle/10665/117497
JournalEMHJ - Eastern Mediterranean Health Journal, 14 (4), 804-809, 2008
MetadataShow full item record
Showing items related by title and MeSH subject.